Davtyan et al. (2019) showed that a combined MultiTEP-based active vaccine — AV-1959R/A targeting the Aβ1–11 epitope plus AV-1980R/A targeting the tau2–18 epitope, adjuvanted with Advax-CpG — induces high-titer antibodies against both Aβ and tau in Tau22/5xFAD bigenic mice, significantly reduces brain soluble and insoluble tau and insoluble Aβ42, and elicits antibodies that bind plaques and tangles in human Alzheimer's brain tissue ex vivo. The study left open whether combined Aβ/tau vaccination can (i) convert pathology reduction into measured cognitive benefit, (ii) achieve balanced high-titer responses to both antigens despite the lower per-antigen titers seen with co-administration, (iii) deliver sex-generalizable efficacy, and (iv) prove safe, durable, and immunogenic in aged, MHC-diverse humans, with antibodies that actually clear aggregates in the human brain.

Background

Alzheimer's disease (AD) is defined at autopsy by two aggregated protein species: extracellular plaques of beta-amyloid (Aβ), a peptide produced by cleavage of the amyloid precursor protein (APP), and intracellular neurofibrillary tangles composed of hyperphosphorylated tau, a microtubule-associated protein. Human biomarker work shows the two pathologies act synergistically — joint amyloid–tau burden predicts metabolic decline and progression to dementia better than either alone — which motivates therapies that hit both simultaneously. Immunotherapy is the leading disease-modifying strategy: passive administration of monoclonal antibodies (e.g., lecanemab) removes existing aggregates but requires lifelong infusions, while active vaccination induces long-lived antibody responses at low cost and is therefore the preferred form for prophylaxis in at-risk but asymptomatic people, where anti-Aβ antibodies appear to work best. The first Aβ vaccine trial (AN1792) was halted for T-cell-mediated brain inflammation, so later vaccines deliberately use short B-cell epitopes (the segments of an antigen that antibodies recognize) without AD-specific T-cell epitopes (the segments that activate T cells and could trigger autoimmune inflammation). Active AD vaccination must still overcome two population-level obstacles: immunosenescence (aged immune systems carry fewer naive T cells and respond weakly to new antigens) and the extreme polymorphism of human MHC class II molecules (the cell-surface proteins that present peptide epitopes to T-helper cells and vary widely between individuals, so any single T-helper epitope covers only part of the population).

The MultiTEP platform was built to solve both problems: it is a recombinant carrier stringing together many promiscuous foreign T-helper epitopes from tetanus toxoid, hepatitis B virus, and influenza — antigens to which most adults already carry memory T cells from prior vaccination or infection. Two MultiTEP-based recombinant protein vaccines were developed for AD: AV-1959R, displaying three copies of the N-terminal Aβ1–11 B-cell epitope, and AV-1980R, displaying three copies of the tau2–18 phosphatase-activating-domain B-cell epitope; both are adjuvanted with Advax-CpG (a delta-inulin-based adjuvant combined with CpG oligodeoxynucleotide, with human-trial safety data).

Davtyan et al. (2019) immunized Tau22/5xFAD (T5x) bigenic mice — an aggressive model carrying a human tau transgene (Thy-Tau22 line) together with APP and presenilin-1 transgenes bearing five familial-AD mutations (5xFAD), so plaque-like and tangle-like pathologies coexist — with AV-1959R/A and AV-1980R/A, separately and in combination. The combined vaccine generated milligram-per-milliliter antibody concentrations against both Aβ and tau; the antibodies recognized plaques, tangles, and neuropil threads in human AD brain sections ex vivo; and vaccination significantly reduced multiple soluble and insoluble tau species and insoluble Aβ42 in mouse brain. Yet the study ended at biochemistry and histology. No behavioral or cognitive endpoints were measured, so the authors themselves flagged that simultaneous reduction of both pathologies should be tested for cognitive benefit, ideally in less aggressive, more translationally relevant models such as APP knock-in mice crossed with humanized tau knock-in mice (mice whose pathological human genes are inserted at their endogenous loci rather than overexpressed from transgenes, better modeling common sporadic AD). The combined formulation elicited lower per-antigen antibody titers than either single vaccine, raising a formulation question about competition between co-administered antigens. Pathology reductions differed between female and male mice (significant insoluble-species reductions were detected mainly in males), and the authors called for larger, sex-separated cohorts. Finally, nothing was known about long-term safety, durability, performance in aged immune systems or across human MHC class II diversity, or whether vaccine-elicited antibodies can actually engage and clear aggregates in the living human brain — where antibody-mediated reduction of pathology could be offset by glial activation through Fc-mediated signaling (antibody Fc regions engaging activating receptors on microglia, the brain's resident immune cells). The source's own glial-marker analysis (GFAP, P2RY12, CD45 — protein markers of astrocyte and microglial activation) surprisingly detected no net change, underscoring that the in-vivo effector mechanism was uncharacterized.

Problem Statement

The overarching objective is to establish whether simultaneous active vaccination against both Aβ and tau — with the MultiTEP-based combination AV-1959R/A (Aβ1–11) plus AV-1980R/A (tau2–18) as the prototype, and successor dual-epitope formulations as parallel instantiations — can become a validated, human-ready disease-modifying (ideally preventive) immunotherapy for Alzheimer's disease. Davtyan et al. (2019) reduced both brain pathologies biochemically but left five gating questions:

  1. Functional efficacy: does simultaneous biochemical reduction of both Aβ and tau by combined vaccination translate into measurable improvement of cognitive and behavioral function — tested not only in aggressive overexpression models but in appropriate, less aggressive, translationally relevant models?

  2. Balanced immunogenicity: why does the combined MultiTEP formulation elicit lower per-antigen antibody titers than single-antigen vaccination, and can formulation modifications — dose, schedule, or antigen-presentation platform — restore balanced high-titer responses to both antigens for the protein-combination formulation?

  3. Sex-dependent efficacy: what mechanism — baseline pathology burden, antibody-titer differences, or sex-specific immune responses — accounts for the different magnitudes of soluble and insoluble Aβ and tau reduction between vaccinated female and male Tau22/5xFAD mice, and does combined-vaccine efficacy differ by sex in adequately powered, sex-stratified cohorts?

  4. Human translation: can long-term safety, durability, and immunogenicity of the combined strategy be established in the context of aged immune systems (immunosenescence) and broad human MHC class II polymorphism, so that a combined Aβ/tau vaccine can advance to first-in-human testing (safety, tolerability, and balanced antibody responses to both antigens at tolerated doses)?

  5. Target engagement in the human brain: how effectively do vaccine-elicited antibodies engage and clear pathological Aβ plaques and tau aggregates in the human brain environment — through what effector mechanism (e.g., Fc-mediated microglial activation versus peripheral sink effects), with what measurable correlates of efficacy in humanized models or humans?

These five questions jointly bound one translational program: each addresses a distinct criterion — efficacy, formulation, population generalizability including sex, safety, and mechanism — for the same combined vaccine strategy, and the source presents them as separate future directions toward human translation.

References

  1. Hayk Davtyan, Armine Hovakimyan, Sepideh Kiani Shabestari, Tatevik Antonyan, Morgan A. Coburn, Karen Zagorski, Gor Chailyan, Irina Petrushina, Olga Svystun, Emma Danhash, Nikolai Petrovsky, David H. Cribbs, Michael G. Agadjanyan, Mathew Blurton-Jones, Anahit Ghochikyan. Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice. Alzheimer's Research & Therapy 11:107 (2019). DOI: 10.1186/s13195-019-0556-2. https://alzres.biomedcentral.com/articles/10.1186/s13195-019-0556-2
  2. Hayk Davtyan, Karen Zagorski, Harinda Rajapaksha, Armine Hovakimyan, Arpine Davtyan, Irina Petrushina, Konstantin Kazarian, David H. Cribbs, Nikolai Petrovsky, Michael G. Agadjanyan, Anahit Ghochikyan. Alzheimer's disease AdvaxCpG-adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules. Scientific Reports 6:28912 (2016). DOI: 10.1038/srep28912. https://doi.org/10.1038/srep28912
  3. Xuejian Feng, Yunyu Hou, Jiaxin Liu, Fei Yan, Mingrui Dai, Mo Chen, Jianan Wang, Jie Li, Zhenjiang Liu, Dong Sun, Yong Zhang, Xianghui Yu, Wei Kong, Hui Wu. A multi-targeting immunotherapy ameliorates multiple facets of Alzheimer's disease in 3xTg mice. npj Vaccines 9:153 (2024). DOI: 10.1038/s41541-024-00942-9. https://doi.org/10.1038/s41541-024-00942-9
  4. Yiting Song, Chun-Ling Dai, Mitsuru Shinohara, Yunn Chyn Tung, Shiqi Zhou, Wei-Chiao Huang, Amal Seffouh, Yuan Luo, Matthew Willadsen, Yang Jiao, Maho Morishima, Yuko Saito, Seong-Ho Koh, Joaquin Ortega, Cheng-Xin Gong, Jonathan F. Lovell. A pentavalent peptide vaccine elicits Aβ and tau antibodies with prophylactic activity in an Alzheimer's disease mouse model. Brain, Behavior, and Immunity 122:185–201 (2024). DOI: 10.1016/j.bbi.2024.08.028. https://doi.org/10.1016/j.bbi.2024.08.028
  5. Chun-Ling Dai, Yiting Song, Yonghua Chen, Yunn Chyn Tung, Wei-Chiao Huang, Xin Gong, Cheng-Xin Gong, Jonathan F. Lovell. Therapeutic nanoliposome vaccine targeting multiple Aβ and tau epitopes reduces AD-like brain pathologies and rescues cognitive deficits in 3xTg-AD mice. Brain, Behavior, & Immunity - Health 51:101167 (2026). DOI: 10.1016/j.bbih.2025.101167. https://doi.org/10.1016/j.bbih.2025.101167
  6. Armine Hovakimyan, Karen Zagorski, Gor Chailyan, Tatevik Antonyan, Levon Melikyan, Irina Petrushina, Dash G. Batt, Olga King, Manush Ghazaryan, Aashrit Donthi, Caitlynn Foose, Nikolai Petrovsky, David H. Cribbs, Michael G. Agadjanyan, Anahit Ghochikyan. Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates. npj Vaccines 7:117 (2022). DOI: 10.1038/s41541-022-00544-3. https://doi.org/10.1038/s41541-022-00544-3
  7. Armine Hovakimyan, Garri Chilingaryan, Olga King, Joia Kai Capocchi, Jean Paul Chadarevian, Hayk Davtyan, Roman Kniazev, Michael G. Agadjanyan, Anahit Ghochikyan. mRNA Vaccine for Alzheimer's Disease: Pilot Study. Vaccines 12(6):659 (2024). DOI: 10.3390/vaccines12060659. https://doi.org/10.3390/vaccines12060659
  8. Karen León-Arcia, Gabriela Pérez-Leal, Heidi Quintero-Álvarez, Diana Iris Zamora-Loyarte, Mailén López-Armenteros, Alexandra de la Caridad Sánchez-Quesada, Yaimeé Vázquez-Mojena. Dual Aβ/tau epitope vaccines: a poorly explored strategy for Alzheimer's disease immunotherapy. Vaccine 61:127414 (2025). DOI: 10.1016/j.vaccine.2025.127414. https://doi.org/10.1016/j.vaccine.2025.127414
  9. Antonella Comitato, Antonino Neri, Andrea Cossarizza. Active Vaccination Strategies for Alzheimer's Disease: An Expanded Review. European Journal of Immunology 56(8):e70250 (2026). DOI: 10.1002/eji.70250. https://doi.org/10.1002/eji.70250
  10. Marina A. Lynch. A case for seeking sex-specific treatments in Alzheimer's disease. Frontiers in Aging Neuroscience 16:1346621 (2024). DOI: 10.3389/fnagi.2024.1346621. https://doi.org/10.3389/fnagi.2024.1346621
  11. Nuravax, Inc. DUVAX: A Phase 1 Study of the Safety and Tolerability of DUVAX, a Dual-Target Alzheimer's Vaccine (Amyloid-Beta and Tau), in Healthy Volunteers. ClinicalTrials.gov registration NCT07142278 (not yet recruiting; estimated start 2026-10-20, estimated completion 2027-07-31). https://clinicaltrials.gov/study/NCT07142278
  12. Nuravax, Inc. A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of AV-1959R in Healthy Participants. ClinicalTrials.gov registration NCT06831812 (completed 2025-12-01). https://clinicaltrials.gov/study/NCT06831812